Clinical Trial

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-09; most recent amendment 2026-04-17.
Trial Details
NCT Number NCT07299747
Lead Sponsor VelaVigo Bio Inc
Conditions Participants With Advanced Solid Tumor Malignancies
Enrollment 255 participants
Start Date 2025-12-04
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-22